RxDoctor Payments DataLook up a doctor →

John Moore, MD

Urology · Little Rock, ARNPI 1669615225

Payments from drug & device makers

$127,925in general payments, 2019–2025

Across 500 payments — averaging $255.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$49K
  • Medtronic$41K
  • Urovant Sciences Inc$11K
  • Angiodynamics, Inc.$9K
  • Sumitomo Pharma America, Inc.$6K
  • Janssen Research & Development, LLC$3K
  • plus $7K from 24 others

What the payments were for

  • Travel & lodging$4,66024%
  • Food & beverage$8,33743%
  • Education$900%
  • Other$6,16732%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$127,925 in reported general payments places this provider in the 85th percentile of 88 urology providers in Arkansas.

See all urology providers in Arkansas

Medicare billing

Part B allowed, 2024
$391,255
Medicare patients
1,161
Services billed
7,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide14$199,948
OrgovyxRelugolix62$162,727
Lupron DepotLeuprolide Acetate21$126,786
GemtesaVibegron66$33,706
MyrbetriqMirabegron57$32,132
Tamsulosin Hcl939$9,158
Oxybutynin Chloride ErOxybutynin Chloride598$9,032
Estradiol137$8,511
Solifenacin Succinate118$3,848
Finasteride348$3,148
Fesoterodine Fumarate ErFesoterodine Fumarate34$2,250
Cephalexin306$1,905
Ciprofloxacin Hcl364$1,498
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen174$1,393
NitrofurantoinNitrofurantoin Macrocrystal58$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$672$232,08071 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$6,361$196,433128 claims
AbbVieLupron Depot$806$126,78621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 88 urology providers in Arkansas.

Other urology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →